As of 2015 June, Kunwha Pharmaceuticals and Dream Pharma start a new journey as one entity under the name of Alvogen Korea through the integration of the two trusted company. Kunwha, a over 50-year-old company with tradition, has diverse therapeutic drug such as nephrology, urology, and anti-infective, and Dream Pharma - a front runner in Korean anti-obesity market - continues to show great promise in development of incrementally modified drugs for treatment of chronic diseases. Alvogen Korea will create synergy through maximizing each of the companies' strengths to become strong and reliable pharmaceutical companies in the industry.
The APAC pharmaceutical industry today continues to experience rapid consolidation by companies with global competitiveness, a trend that has manifested itself through Alvogen’s moves in the region since 2012 Kunwha acquisition. Together with Lotus in Taiwan, Alvogen Korea will hold a major strategic position for the growth in the APAC region. And we will reinforce investment to achieve a regional leading position in APAC.
Our vision is to become a company that opens up a new horizon in the pharmaceutical business. We have the ambition to become a APAC TOP 5 player by securing various business models that comply with market demands and the best technology that will help us be the first in market.
Alvogen is building a regional platform for growth across the APAC region, with commercial network in 10 countries. The company has manufacturing and R&D centers in Korea and Taiwan and hundreds of products on the market.
Alvogen’s Asia Pacific commercial hub currently encompasses a broad range of countries including Korea, Taiwan, Myanmar, Thailand, Vietnam, Philippines, Malaysia, Hong Kong and China.